Avedro announced two new studies at the XXXIV Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) evaluating non-surgical photorefractive intrastromal corneal collagen cross-linking, or PiXL, to treat low myopia.

The two studies, one at Ruhr University Eye Hospital in Germany and the second at Eagle Eye Centre in Singapore found that PiXL was safe and effective in treating low myopia.

Dr. Lim Wee Kiak of Eagle Eye Centre in Singapore noted that “[c]urrent refractive procedures are invasive and weaken the cornea. PiXL is revolutionary in that it improves the refractive error by stiffening the cornea, while also being non-invasive.”

The PiXL procedure, developed by Avedra, offers the potential to provide non-invasive vision improvement for low myopia without compromising corneal biomechanical integrity. PiXL treats myopic refractive errors through the topical application of riboflavin followed by exposure of the cornea to UVA light delivered by the Mosaic device, which uses eye-tracking technology in order to deliver controlled cross-linking.

Click here ^[1] to read the full release.